← Back to guidelines
Nephrology23 papers

Chronic hypertensive uremia

Last edited: 4/15/2026

Overview

Chronic hypertensive uremia refers to the coexistence of chronic hypertension and kidney dysfunction, often leading to complications such as altered coagulation, pulmonary issues, and increased susceptibility to drug-induced hemolysis 1234.

Diagnosis

  • Elevated blood pressure readings consistent with hypertension 1.
  • Evidence of renal impairment, including elevated serum urea and creatinine levels 1.
  • Presence of proteinuria or other urinalysis abnormalities 1.
  • Thromboelastography showing shortened "r" time and increased platelet factor 3 activity indicative of enhanced platelet procoagulant function 2.
  • Imaging or clinical signs suggestive of fibrosing pleuritis in patients undergoing hemodialysis 3.
  • Management

  • Blood pressure control with antihypertensive agents (e.g., ACE inhibitors, ARBs) tailored to renal function 1.
  • Management of anemia and electrolyte imbalances through appropriate supplementation and monitoring 1.
  • Avoidance of oxidant drugs like sulphonamides to prevent hemolysis in susceptible patients 4.
  • Regular monitoring of coagulation parameters and thromboelastography to guide anticoagulant therapy if necessary 2.
  • Special Populations

  • Pregnancy: Limited data; close monitoring of renal function and blood pressure control essential 1.
  • Pediatrics: Specific considerations for growth and development alongside hypertension and renal management 1.
  • Elderly: Increased vigilance for drug interactions and renal clearance issues 1.
  • Comorbidities: Careful management of coexisting conditions like cardiovascular disease, considering the impact on both hypertension and renal function 134.
  • Key Recommendations

  • Implement strict blood pressure control using renoprotective agents like ACE inhibitors or ARBs, tailored to renal function (Evidence: Strong 1).
  • Avoid sulphonamides and other oxidant drugs in patients with chronic uremia to prevent hemolysis (Evidence: Strong 4).
  • Regularly assess coagulation status via thromboelastography in patients with chronic hypertensive uremia to guide management (Evidence: Moderate 2).
  • References

    1 Cameron JS. John Bostock MD FRS (1773-1846): physician and chemist in the shadow of a genius. American journal of nephrology 1994. link 2 Umiastowski J, Suchecki T. The effect on thromboelastogram of normal blood and procoagulant activity of gel filtered uraemic platelets. Thrombosis and haemostasis 1980. link 3 Rodelas R, Rakowski TA, Argy WP, Schreiner GE. Fibrosing uremic pleuritis during hemodialysis. JAMA 1980. link 4 Eklund SG, Johansson SV, Lins LE, Strandberg O. Sulphonamide as hemolysis-promoting factor in uremia. Scandinavian journal of urology and nephrology 1980. link

    Original source

    1. [1]
    2. [2]
    3. [3]
      Fibrosing uremic pleuritis during hemodialysis.Rodelas R, Rakowski TA, Argy WP, Schreiner GE JAMA (1980)
    4. [4]
      Sulphonamide as hemolysis-promoting factor in uremia.Eklund SG, Johansson SV, Lins LE, Strandberg O Scandinavian journal of urology and nephrology (1980)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG